References
- World Health Organization. 2012. Epilepsy-Fact Sheet.
- Pellock JM, Faught E, Leppik IE, et al. Felbamate: consensus of current clinical experience. Epilepsy Res. 2006;71:89–101.
- Hwang H, Kim KJ. New antiepileptic drugs in pediatric epilepsy. Brain Dev. 2008;30:549–555.
- Dieckhaus CM, Thompson CD, Roller SG, et al. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact. 2002;142:99–117.
- Roecklein BA, Sacks HJ, Mortko H, et al. Fluorofelbamate. Neurotherapeutics. 2007;4:97–101.
- French JA. Refractory epilepsy: clinical overview. Epilepsia. 2007;48(Suppl 1):3–7.
- Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia. 2008;49(Suppl 1):8–12.
- Granata T, Marchi N, Carlton E, et al. Management of the patient with medically refractory epilepsy. Expert Rev Neurother. 2009;9:1791–1802.
- Coppola G. Treatment of partial seizures in childhood. CNS Drugs. 2004;18:133–156.
- Schering-Plough restricts felbamate. React Wkly &NA. 1994;515:2.
- Henahan S. Unexpected fate for felbamate. Inpharma Wkly &NA. 1994; 3.
- US FDA Felbamate - Drugs@FDA [Internet]. FDA Approv. drug Prod. 2014 [cited 2014 Feb]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails.
- MEDA Pharmaceuticals Inc. FELBATOL® (felbamate) Tablets 400 mg and 600 mg, Oral Suspension 600 mg/5 mL - Label information. Somerset (NJ): MEDA Pharmaceuticals Inc; 2012.
- Borowicz KK, Piskorska B, Kimber-Trojnar Z, et al. Is there any future for felbamate treatment? Pol J Pharmacol. 2004;56:289–294.
- Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf. 1999;21:225–239.
- Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem. 2005;5:3.
- Arakawa M, Ito Y. N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology. Cerebellum. 2007;6:308–314.
- Wu G, Fang Y-Z, Yang S, et al. Glutathione metabolism and its implications for health. J Nutr. 2004;134:489–492.
- Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33:2187–2199.
- Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36:78–86.
- Novartis. Clozaril (Clozapine) [drug label]. Drugs at FDA: Novartis; Revised 09/2015.